Limitations
SECONDARY
This study had several limitations. In the SWOG 1216 trial, orteronel improved PFS but not OS, and therefore is not being used in the current practice, which may have limited the generalizability of this study in the clinical setting compared with other ARPIs. Also, while to our knowledge this trial enrolled the largest proportion of Black patients in the mCSPC setting to date, the sample size of the primary trial may not be sufficient for the subgroup analyses of Black patients or to detect small effect sizes. This can limit the statistical power of the secondary analysis. We acknowledge that this is an exploratory analysis in nature and should be interpreted with caution.